USP36 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL22617019	1.00	20/20
SCHEMBL22617021	1.00	20/20
SCHEMBL22617039	1.00	20/20
SCHEMBL22617229	1.00	20/20
SCHEMBL22617230	1.00	20/20
SCHEMBL22617016	0.74	20/20
SCHEMBL22617058	0.65	19/20
SCHEMBL22617068	1.00	16/20
SCHEMBL22236223	0.50	14/20
SCHEMBL22617189	1.00	13/20
SCHEMBL22617096	1.00	12/20
SCHEMBL22617035	0.66	12/20
SCHEMBL22258418	0.45	11/20
SCHEMBL22617026	0.61	10/20
SCHEMBL22617066	0.67	9/20
SCHEMBL22617166	0.63	8/20
SCHEMBL18246233	0.47	8/20
SCHEMBL18988941	0.49	7/20
SCHEMBL5148493	0.46	7/20
SCHEMBL15859818	0.40	7/20

Clinical trials — most relevant to USP36 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Collection of Samples and Clinical Data From Patients With Amyloid Diseases	nan	RECRUITING
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee	nan	COMPLETED
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey	nan	COMPLETED
Timecourse of Immobilization Experiment	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP36 binder may also engage these)

Protein	Name	Similarity
B1AQJ2	—	1.000	B1AQJ2 →
Q9H9J4	—	1.000	Q9H9J4 →
E1B9W9	—	1.000	E1B9W9 →
B2RQC2	—	1.000	B2RQC2 →
D3ZU96	—	0.999	D3ZU96 →
Q76I79	—	0.994	Q76I79 →
Q2PFD7	—	0.994	Q2PFD7 →
Q8C0C0	—	0.992	Q8C0C0 →
P48382	—	0.992	P48382 →
P0C2N5	—	0.992	P0C2N5 →
A6QP06	—	0.992	A6QP06 →
Q8BWQ5	—	0.992	Q8BWQ5 →
Q66H04	—	0.992	Q66H04 →
Q5DW34	—	0.992	Q5DW34 →
O95402	—	0.992	O95402 →
Q7TN02	—	0.992	Q7TN02 →
Q8K3A9	—	0.992	Q8K3A9 →
Q9NYI0	—	0.991	Q9NYI0 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.991	landscape →
A6QLA6	—	0.991	A6QLA6 →
CBX4	E3 SUMO-protein ligase CBX4	0.991	landscape →
Q8BZ32	—	0.991	Q8BZ32 →
Q9EPW2	—	0.991	Q9EPW2 →
E1BE02	—	0.991	E1BE02 →
CDKL5	Cyclin-dependent kinase-like 5	0.991	landscape →
Q3U8K7	—	0.990	Q3U8K7 →
USP19	Ubiquitin carboxyl-terminal hydrolase 19	0.990	landscape →
P10244	—	0.990	P10244 →
Q9H329	—	0.990	Q9H329 →
Q8BZT2	—	0.990	Q8BZT2 →